ArticleZebrafish2008
Small molecule modifier screen for kit-dependent functions in zebrafish embryonic melanocytes.
Article in Zebrafish, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Papaverine: A Miraculous Alkaloid from Opium and Its Multimedicinal Application.Molecules (Basel, Switzerland) · 2023Review
- Application of the Transcriptional Disease Signature (TDSs) to Screen Melanoma-Effective Compounds in a Small Fish Model.Scientific reports · 2019Article
- Developmental toxicity assay using high content screening of zebrafish embryos.Journal of applied toxicology : JAT · 2015Article
- Origins of adult pigmentation: diversity in pigment stem cell lineages and implications for pattern evolution.Pigment cell & melanoma research · 2015Review
- Targeting melanocyte and melanoma stem cells by 8-hydroxy-2-dipropylaminotetralin.Archives of biochemistry and biophysics · 2014Article
- Antiproliferative effect of the isoquinoline alkaloid papaverine in hepatocarcinoma HepG-2 cells--inhibition of telomerase and induction of senescence.Molecules (Basel, Switzerland) · 2014Article
- Clonal and lineage analysis of melanocyte stem cells and their progeny in the zebrafish.Methods in molecular biology (Clifton, N.J.) · 2012Article
- Studying synthetic lethal interactions in the zebrafish system: insight into disease genes and mechanisms.Disease models & mechanisms · 2012Review
- In vivo imaging and quantitative analysis of changes in axon length using transgenic zebrafish embryos.Neurotoxicology and teratologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Zebrafish is gaining popularity as a vertebrate model for screening small molecules that affect specific phenotypes or genetic pathways. In this study, we present a targeted drug screen to identify drug modifiers of the melanocyte migration defect of a temperature-sensitive allele of the Kit receptor tyrosine kinase, kit(ts). We first test two candidate drugs, the phosphatidylinositol-3-kinase kinase inhibitor (LY294002) and the Erk/MAP kinase inhibitor (PD98059), for their effect on melanocyte migration and survival. We find that LY294002 enhances the migration defect of kit(ts), implicating the phosphatidylinositol-3-kinase kinase pathway in promoting kit-dependent melanocyte migration, but not survival. We then used the kit(ts)-sensitized genetic background to screen a panel of 1280 pharmacologically active drugs to identify drug enhancers and suppressors of the kit(ts) melanocyte migration defect. We identified three drug enhancers of migration, two of which, Papaverine and Isoliquiritigenin, specifically enhance the kit(ts) migration defect, while 8-DPAT affected both melanocyte migration and survival. These drugs now provide additional experimental tools for investigating the mechanisms of kit-promoted melanocyte migration and survival in the zebrafish embryo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.